Romosozumab, an anti-sclerostin treatment, presents a promising avenue for preventing and treating fractures in osteoporosis among postmenopausal women; however, potential negative cardiovascular effects need careful consideration [41,68,70,71]. The gene discussed is SOST; the disease is osteoporosis.